Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ET-600
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
Details : Through the acquisition, Eton will expand its portfolio with ET-600 which is an innovative product candidate under development for the treatment of an endocrinology condition.
Brand Name : ET-600
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 15, 2023
Lead Product(s) : ET-600
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?